If You Haven’t Already Bought Micron, Here’s Why
Micron Technology races higher on AI memory demand and supply tightness. This piece outlines why investors may consid...
Investing
Learn smart investing strategies for stocks, ETFs, bonds, and building long-term wealth.
5,594 articlesFinance Guru: Geopolitical Conflicts Spur Market Turbulence
Geopolitical conflicts are upending the classic playbook for U.S. stocks. The S&P 500 has not followed the traditiona...
Dave Ramsey: You Can’t Save While Buried in $86K Debt
A near-40 couple carries $86,000 in debt as they earn $200,000 a year and wonder if they should invest now or pay dow...
Ondas Just Unlocked Billion in DoD Deals After Mistral Merge
Ondas Holdings rides a Mistral merger to prime DoD contractor status, unlocking access to more than $1 billion in def...
Anthropic Ratchets Pentagon Battle: Private Deals at Risk
Anthropic has filed a federal lawsuit after being labeled a supply-chain risk by the government, arguing the move thr...
Ticketmaster Settlement Good News for Markets, Bad for Fans
A fresh settlement involving Ticketmaster sparked a rally in Live Nation shares, signaling investor relief but stirri...
Goldman Sees $5,400 Gold: What It Means for DUST Investors
A Goldman Sachs note presents a bullish scenario where gold could hit $5,400 per ounce. The outlook reverberates thro...
Retirees Still Collecting Quarterly Dividends From Aging ETF
Dividend-focused ETFs remain a fixture for retirement income, but a shifting rate landscape tests how long these fund...
Retirees Eyeing EMLC’s 5.75% Yield, Wall Street Bets
A growing slice of retirees is looking at the EM Local Currency Bond ETF for a higher income stream. But currency swi...
Poland’s Wild Stock Market: The ETF Play to Watch Now
Poland’s wild stock market is capturing renewed interest as diversification in Europe. The iShares Poland ETF offers ...
Pharmaceuticals Trio Draw Buy Ratings Ahead of 2026 Catalysts
A trio of small-cap biotechs—X4 Pharmaceuticals, Immuneering, and Tango Therapeutics—are attracting new and renewed a...
UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...